55Cobalt complexes with pendant carbohydrates as potential PET imaging agents

Applied Radiation and Isotopes

Volumn 65, Issue 12, 2007, Pages 1303-1308

  Ferreira, Cara L ^a,b   Lapi, Suzanne ^a,c   Steele, Jennifer ^b   Green, David E ^b   Ruth, Thomas J ^a   Adam, Michael J ^a   Orvig, Chris ^b  

^a TRIUMF   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

55Co; Carbohydrates; Cobalt; PET

Indexed keywords

BIS LIGAND COBALTS; COBALT COMPLEXES; NON RADIOACTIVE COMPLEXES; RADIOLABELED COMPOUNDS;

CARBOHYDRATES; CHEMICAL ANALYSIS; DRUG PRODUCTS; INFRARED RADIATION; LIGANDS; MASS SPECTROMETRY; POLYETHYLENE TEREPHTHALATES; ULTRAVIOLET SPECTROSCOPY;

COBALT COMPOUNDS;

BIS[1 (4 PHENYL BETA DEXTRO GLUCOPYRANOSIDE) 2 METHYL 3 OXY 4(1H) PYRIDINATO]COBALT(II) PENTAHYDRATE; BIS[1 [N (2 AMINO 2 DEOXY DEXTRO GLUCOPYRANOSE)ETHANAMIDE] 2 METHYL 3 OXY 4(1H) PYRIDINATO]COBALT(II) PENTAHYDRATE; BIS[1 [N (4 BENZYL BETA DEXTRO GLUCOPYRANOSIDE)ETHANAMIDE] 2 METHYL 3 OXY 4(1H) PYRIDINATO]COBALT(II) HEPTAHYDRATE; BIS[1 [N (METHYL 6 AMINO 6 DEOXY ALPHA DEXTRO GLUCOPYRANOSIDE) ETHANAMIDE] 2 METHYL 3 OXY 4(1H) PYRIDINATO]COBALT(II) TRISHYDRATE; COBALT COMPLEX; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBOHYDRATE; COBALT; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ARTICLE; CHEMICAL ANALYSIS; DRUG IDENTIFICATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; ISOTOPE LABELING; MASS SPECTROMETRY; MICROSCOPY; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY; CHEMICAL STRUCTURE; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; POSITRON EMISSION TOMOGRAPHY; SPECTROPHOTOMETRY; SYNTHESIS;

CARBOHYDRATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COBALT RADIOISOTOPES; HUMANS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 35649016104     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2007.06.003     Document Type: Article

References (18)

1. Al Saleh F.S., Al Mugren K.S., and Azzam A. Excitation functions of (p,x) reactions on natural nickel between proton energies of 2.7 and 27.5 MeV. Appl. Radiat. Isot. 65 (2007) 104-113
2. Clarke E.T., and Martell A.E. Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridnone chelates of divalent and trivalent metal ions. Inorg. Chim. Acta 191 (1992) 56-63
3. Cotton F.A., Wilkinson G., and Gaus P.L. Basic Inorganic Chemistry (1995), Wiley, New York
4. Czernin J. Clinical application of FDG-PET in oncology. Acta Med. Austriaca 5 (2002) 162-170
5. De Reuck J., Paemeleire K., Santens P., Strickmans K., and Lemahieu I. Cobalt-55 positron emission tomography in symptomatic atherosclerotic carotid artery disease: borderzone versus territorial infarcts. Clin. Neurol. Neurosurg. 106 (2004) 77-81
6. De Reuck J., Santens P., Strickmans K., and Lemahieu I. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J. Neurol. Sci. 193 (2001) 1-6
7. De Reuck J., Vonck K., Santens P., Boon P., De Bleecker J., Strickmans K., and Lemahieu I. Cobalt-55 positron emission tomography in late-onset epileptic seizures after thrombo-embolic middle cerebral atery infaction. J. Neurol. Sci. 181 (2000) 13-18
8. Front D., Israel O., Iosilevsky G., Even-Sapir E., Frenkel A., Peleg H., Steiner M., Kuten A., and Kolodny G.M. Human lung tumors: SPECT quantitation of differences in Co-57 bleomycin uptake. Radiology 165 (1987) 129-133
9. 55Co-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. Nucl. Med. Biol. 27 (2000) 77-81
10. Green D.E., Ferreira C.L., Stick R.V., Patrick B.O., Adam M.J., and Orvig C. Carbohydrate-bearing 3-hydroxy-4-pyridinato complexes of gallium(III) and indium(III). Bioconjugate Chem 16 (2005) 1597-1609
11. Jansen H.M.L., Pruim J., Vliet A.M., Hew J.M., Fanssen E.J., de Jong B.M., Kosterink J.G., Haaxma R., and Korf J. Visualization of damaged brain tissue after ischemic stroke with cobalt-55 positron emission tomography. J. Nucl. Med. 35 (1994) 456-460
12. Joosten A.A., Jansen H.M.L., Piers D.A., Minderhoud J.M., and Korf J. Cobalt-57 SPET in relapsing-progressive multiple sclerosis: a pilot study. Nucl. Med. Commun. 16 (1995) 703-705
13. Jurisson S., Berning D., Jia W., and Ma D. Coordination compounds in nuclear medicine. Chem. Rev. 93 (1993) 1137-1156
14. Krohn K.A., Mankoff D.A., Muzi M., Link J.M., and Spence A.M. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl. Med. Biol. 32 (2005) 663-671
15. Ma R., Reibenspies J., and Martell A.E. Stabilities of 1,2-diethyl-3-hydroxy-4-pyridnone chelates of divalent and trivalent metal ions. Inorg. Chim. Acta 223 (1994) 21-29
16. Segall G. Assessment of myocardial viability by positron emission tomography. Nucl. Med. Commun. 23 (2002) 323-330
17. 58Ni. Appl. Radiat. Isot. 49 (1998) 1519-1522
18. Stevens H., Knollema S., Piers D.A., Van De Wiele C., Jansen H.M.L., De Jager A.E.J., De Reuck J., Dierckx R., and Korf J. Cobalt-57 as a SPET tracer in the visualization of ischemic brain damage in patients with middle cerebral artery stroke. Nucl. Med. Commun. 19 (1998) 573-580